Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

BeiGene PD-(L)1 Inhibitor Approved in US for Esophageal Carcinoma

publication date: Mar 18, 2024

BeiGene was approved to market Tevimbra® (tislelizumab-jsgr) in the US for patients with unresectable or metastatic esophageal squamous cell carcinoma. Patients must have previously been treated with chemotherapy that did not include a PD-(L)1 inhibitor. The approval took a very long 20 months because US regulators were not allowed to inspect BeiGene’s manufacturing plant due to COVID restrictions. At one point, BeiGene had out-licensed Tevimbra to Novartis in a $2.2 billion deal ($650 million upfront). Novartis returned the rights to BeiGene six months ago, claiming that regulatory problems soured the deal. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital